Business
Awarded further Bicycle Therapeutics contract
Awarded further Bicycle Therapeutics contract.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n \n RNS Number : 8165I\n Physiomics PLC\n 06 April 2020\n \n \n \n \n \n 6 April 2020\n \n \n Physiomics plc \n \n \n (\"Physiomics\") or (the \"Company\")\n \n \n \n \n \n \n Physiomics awarded further contract by Bicycle Therapeutics\n \n \n \n \n Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by its existing client, Bicycle Therapeutics (\"Bicycle\") (the \"Project\").\n \n \n \n \n The Project is an extension of the work the Company completed on Bicycle's lead programme, BT1718 (currently in a Cancer Research UK-sponsored Phase I/IIa study), which Physiomics announced on 8 July 2019. Physiomics' role is related to the analysis of clinical data from this trial and its work on the initial project was acknowledged in a poster presentation, at the ESMO conference, in September 2019(1). The Project is expected to be completed in the next six months.\n \n \n \n \n \n \n Dr Jim Millen, CEO said\n \n : \"We are delighted to continue to expand our relationship with Bicycle Therapeutics, which is rapidly becoming a key high-profile client. It's also pleasing that we are able to sign new business in the current environment and hope to see this continue over the course of the rest of this calendar year.\"\n \n \n \n \n (1)https://www.bicycletherapeutics.com/wp-content/uploads/ESMO-Sep-2019-FINAL.pdf\n \n \n \n \n Enquiries:\n \n Physiomics plc \n Dr Jim Millen, CEO\n +44 (0)1865 784 980\n \n Strand Hanson Ltd (NOMAD)\n Richard Tulloch & James Dance\n +44 (0) 20 7409 3494\n \n \n Hybridan LLP (broker)\n \n Claire Louise Noyce\n +44 (0) 203 764 2341\n \n Notes to Editor\n \n \n About Physiomics\n \n \n \n \n \n Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate ...